Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
Clinical trial NCT04065165 · WITHDRAWN
Trial details
- NCT number
- NCT04065165
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Status
- WITHDRAWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-01
- Primary completion
- 2023-07-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.